Thus, dual PHD and BCL-2 inhibition act in concert to efficiently promote AML cell apoptosis, decrease AML burden and prolong mouse survival, revealing a promising therapeutic strategy in AML treatment. This evidence concerns the gene BCL2 and acute myeloid leukemia.